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Abstract 
Studies in experimental animals show apparent transmissibility of amyloidogenic proteins associated with 
prion, Alzheimer’s, Parkinson’s or other neurodegenerative diseases. While these data raise potential 
concerns for public health, convincing evidence for human iatrogenic transmission currently only exists 
for prions and for β-amyloid (Aβ) after systemic injections of contaminated cadaver-derived growth 
hormone extracts or dura mater grafts. While these procedures are now obsolete, recent reports raise 
the possibility of iatrogenic Aβ transmission through putatively contaminated neurosurgical equipment.  
Iatrogenic Aβ-transmission appears to cause amyloid deposition in brain parenchyma and blood vessel 
walls, resulting in cerebral amyloid angiopathy (CAA) after several decades. CAA can cause life-threatening 
brain haemorrhages, yet there is currently no proof that Aβ-transmission could also lead to Alzheimer's 
dementia. Longer term, larger scale epidemiological studies and sensitive, cost-efficient amyloid detection 
tools are needed to better understand potential Aβ transmission routes and clarify whether other 












Proteinopathies are diseases characterized by the presence of misfolded proteins that adopt an aberrant 
conformation and can provide a template for their own polymerization. These include neurological 
disorders such as prion diseases and common neurodegenerative disorders such as Alzheimer's (AD), 
Parkinson's (PD) and Huntington's (HD) disease. While prion diseases are the prototype of transmissible 
proteinopathies, misfolded proteins characteristic of AD and PD (Aβ, tau or α-synuclein) also exhibit 
properties similar to those of prions in experimental systems: self-replicating, β-sheet rich ordered protein 
assemblies termed amyloids, and possible transcellular propagation1. In humans, such protein 
aggregation is associated with neurodegeneration and clinical impairments2. 
Over the last years, increasing evidence has indicated prion-like mechanisms of protein polymerization to 
also operate in more common amyloid-associated diseases. This has led to increasing worries with regard 
to the possibility of iatrogenic amyloid transmissibility in humans1. Two research groups reported last year 
cases of putative contamination by neurosurgical instruments3,4. This raises questions with regard to 
public health and safety of laboratory investigators, and makes the distinction between known infectious 
prions and other protein aggregates more blurred. In October 2019 a group of international experts across 
different fields (cellular/molecular biology, neurosurgery, blood transfusion, public health) gathered to 
discuss these latest findings and address the following questions: (1) What is the evidence that 
proteinopathies causing neurodegeneration can be transmitted between humans? (2) Under what 
conditions does such human-to-human transmission occur? (3) What research is needed to fully 
understand the potential risks and develop efficient protective measures? This personal view outlines key 
conclusions and priorities for further research based on a systematic review of the latest available 
literature. 
Evidence of amyloid transmissibility from experimental inoculation of animals  
While discussions on terminology are ongoing (Box 1), for the purpose of this Personal View we will use 
the term “prion” for agents that cause Transmissible Spongiform Encephalopathies (TSEs) and 
“proteopathic seed”5 to describe all aggregated proteins that have seeding and propagation properties in 
vitro or in animals. 
Apparent transmission of abnormally folded proteins associated with AD, PD, HD, amyotrophic lateral 
sclerosis and frontotemporal lobar degeneration has been demonstrated in animal models and cell 
culture6,7. Injection of minute amounts of proteopathic seed-containing material, especially aggregates of 
Aβ, into the brain are sufficient to induce cerebral amyloidosis in amyloid precursor protein 
overexpressing transgenic (APP) mice8. Formation of pathological aggregates can be distant from the 
injection site8. Moreover, Aβ seeds injected intravenously or intraperitoneally can induce CAA in rodents 
and primates9,10. Cerebral microhaemorrhage was also observed in wild-type mice after 12 months of 
parabiosis with their APP/human mutant presenilin 1 (PS1) transgenic littermates11. We refer to other 
publications for an in-depth overview and critical discussion of these experiments and their 
implications5,6,10,12,13. These findings in experimental models have raised concern that extracellular Aβ and 
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even intracellular proteins associated with neurodegenerative diseases, such as tau and α-synuclein,  
might be transmitted from human to human, similar to infectious prions.  
Amyloid transmissibility between and into humans 
In the case of prions, human transmission has been observed in the context of mortuary feasts in Papua 
New Guinea as well as through medical procedures such as corneal transplantation, neurosurgical 
instruments, stereotactic depth electrodes, treatment with human cadaveric pituitary hormones such as 
growth hormone (c-hGH) and gonadotrophin, cadaveric dura mater grafts and, in the case of variant CJD, 
blood transfusion14,15. The biggest threat to public health was however bovine spongiform 
encephalopathy (BSE), as the bovine agent was able to cross the species barrier into human, causing the 
variant CJD outbreak in consumers exposed to contaminated meat and cattle products. Below we review 
the evidence that Aβ seeds can be transmitted through human-to-human routes (Table 1). We start with 
the strongest evidence first.  
Growth hormone treatment and dura mater graft 
Extracts of growth hormone from pituitary glands collected post-mortem were used between 1958 until 
the mid-1980s for treatment of growth hormone deficiency16. Human dura mater grafts were used until 
the mid-1990’s, mainly for repair of dural defects during neurosurgery but also for cardiac, orthopaedic, 
otological, dental, urological, and gynaecological procedures17. In addition to prions, pathological deposits 
of Aβ, tau and α-synuclein may sometimes be observed in pituitary glands and dura mater, even if the 
tissue was collected from donors without clinical signs of neurodegenerative disease18,19. A first 
retrospective study of 796 deceased individuals treated with hGH derived from human cadavers (c-hGH) 
did not reveal any increased risk of AD or PD18. This study was limited in scope as CAA or intracerebral 
haemorrhage were not investigated, autopsy data were not available, and the mean duration from first 
treatment was 16.3 years, likely too short to detect clinical documentation of CAA-related complications. 
The authors accordingly recommended further monitoring of the cohorts. 
This view has changed since the discovery of CAA and parenchymal Aβ pathology in patients who died of 
iatrogenic CJD (iCJD) (Table 1). Post-mortem histopathological analyses performed on 80 c-hGH recipients 
who developed iCJD, and on 12 c-hGH recipients who did not develop CJD, revealed that 31 cases (34%) 
exhibited Aβ deposits and/or CAA (Table 1). While sporadic CAA is typically observed in people after the 
sixth decade of life20, here all affected individuals were aged between 20 and 54 years. Genetic studies did 
not identify any risk factors associated with early onset CAA in these iCJD patients21. Three additional 
findings argue in favour of iatrogenic transmission of Aβ seeds in these patients, independent of the prion 
pathology. First, several c-hGH samples prepared before 1988 were found to contain tau and Aβ 
peptides10,22 and  these samples accelerated Aβ plaque formation and induced CAA when injected in the 
brain of mice expressing a humanised Aβ domain10. Second, there is no evidence of increased Aβ 
pathology in other post-mortem prion disease cohorts (sporadic or variant CJD, inherited prion 
diseases)21,23, and no evidence for cross-seeding between Aβ and prions24. Finally, 5 of 12 (42%) individuals 
who had received c-hGH treatment and did not develop CJD, showed CAA and parenchymal Aβ pathology 
at autopsy25. 
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Similar analyses have been performed on 45 individuals who received dura mater grafts: 44 cases with a 
neurosurgical procedure (40 of whom later developed iCJD), and 1 case with cardiac embolisation (Table 
1). Thirty-two of these individuals (70%) had CAA. In nearly all the cases, Aβ deposition was also observed 
in the parenchyma (Table 1). Again, most of these individuals were much younger compared to typical 
patients with sporadic CAA. The distribution of the Aβ deposits was consistent with propagation from the 
allografted dura19,26. 
Neurosurgical instruments 
Experiments showing that contaminated stainless-steel wires can transmit Aβ pathology in mice8 raised 
concerns that Aβ proteopathic seeds might be transmitted during neurosurgical procedures. Recent 
publications reported 11 patients with a medical history of neurosurgical intervention at a very young age 
who developed CAA-related intracerebral haemorrhages at ages 30-573,4,20 (Table 1). The age of onset of 
CAA in these patients suggests that surgical instruments may have transmitted Aβ seeds during the 
procedure many years earlier. This prolonged latency would be consistent with other evidence that Aβ 
accumulates very slowly and that it may take over two decades to develop symptomatic pathology 
(typically associated with extracellular Aβ and intracellular tau tangles)27. While the limited number of 
documented cases and the retrospective nature of these studies preclude conclusions of a causal 
relationship between early neurosurgical procedure and CAA in these young or middle-aged adults, they 
clearly signal the need for vigilance and further systematic study of this possible phenomenon.  
Overall, 74 cases of suspected iatrogenic transmission of Aβ pathology have been published (Table 1), 57 
of which concern individuals below the age of 50. Together with the inconsistent tau pathology (Table 1), 
the absence of cognitive impairment in these 74 individuals argues against transmission of a full AD 
neuropathological and clinical phenotype. Importantly, however, there is a considerable latency - in most 
cases well in excess of 20 years - between the presumed iatrogenic exposure and the manifestation of 
vascular Aβ pathology and the link between such clinical manifestation and very early neurosurgery might 
have escaped attention in many cases. These considerations raise the possibility that the present data 
may underestimate the risk of potential iatrogenic transmission of Aβ seeds.  
Blood transfusion 
While 4 cases of probable blood transfusion-mediated transmission of variant CJD - before the 
introduction of blood product leucodepletion throughout Europe - have been reported, there is no 
evidence for such transmission of sporadic CJD28. Importantly, epidemiological analysis of the cause of 
death of more than 6,000 haemophiliacs (who received abundant blood products via plasma protein 
therapy throughout their lives) did not detect an increased risk of central nervous system disease 
compared with the general population29. The most rigorous study took advantage of the excellent 
documentation of blood banking in Denmark and Sweden: the Scandinavian Donations and Transfusions 
(SCANDAT2) electronic database. Among 1,465,845 individuals transfused between 1968 and 2012, 2.9% 
received at least 1 unit of blood from a donor who was diagnosed with a neurodegenerative disorder (AD, 
PD, or unspecified dementia) within 20 years after donation (median follow-up: 10.4 years). The authors 
found no evidence of transmission of AD by blood transfusion - there was no disease concordance 
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between donors and their recipients, nor between recipients of blood from the same donor30. An obvious 
limitation is that no autopsy or biomarker data were available to support the diagnoses in donors or 
recipients. Association between blood transfusion and CAA (i.e. brain haemorrhage suggestive of or 
histological evidence of CAA) was not studied. Continued long term follow-up with a focus on the 
prevalence of both neurodegenerative disorders and CAA in patients receiving blood transfusions is 
needed.  
  
Future research priorities 
The use of c-hGH was terminated in the mid-1980s, and the use of cadaver-derived dura mater products 
for medical procedures was discontinued more than 20 years ago. Blood transfusion and neurosurgery on 
the other hand are lifesaving to millions of patients worldwide every year. Given the high prevalence of 
neurodegenerative diseases such as AD, especially in elderly populations31, more systematic monitoring 
of the risk of Aβ pathology transmission in these common procedures is needed. For other amyloids, such 
as α-synuclein, tau, Htt, SOD1 or TDP436,7, the absence of evidence for transmission between humans 
(e.g. the lack of statistical difference between tau neuronal pathology in iatrogenic and sporadic CJD 23,25,32) 
is not evidence of absence of risk. Since such proteopathic seeds are apparently efficiently transferred 
after extracellular injections in experimental animals6,7, this possibility must be evaluated more closely in 
humans. 
One of the biggest gaps in our knowledge is the lack of understanding of the molecular nature of 
proteopathic seeds. While only 36 human proteins are officially recognized as amyloids causing 
aggregates associated with diseases33, there are aggregation-determining (amyloid-like) regions in most 
proteins34. Recent cryo-EM and solid-state NMR studies have started to unravel the complex 
heterogeneity of protein aggregates involved in neurodegenerative disorders35. It is crucial to continue 
this work and to determine the structural conformations of different proteopathic seeds, correlating their 
structural and biochemical characteristics with their neurotoxic properties and propensity to spread. This 
will require the development of physiologically relevant dose-response toxicity assays, both in vitro and 
in vivo. It is worth noting that synthetic Aβ aggregates generally have poor seeding capacity36, suggesting 
that other factors may accelerate the seeding process and lead to neurodegeneration. Cell biological 
studies are also needed to fully understand amyloid pathology spreading, including the role of proteins 
possibly involved in modulating spreading and toxicity, such as the cellular prion protein37,38. Identifying 
the environmental and physicochemical/cellular host factors promoting or delaying the development of 
pathology (apart from the ageing process) will contribute to uncovering risk factors, and to devising 
strategies to prevent seed formation and polymerization in vivo. 
A precise description of the molecular nature of proteopathic seeds will also help devise novel detection 
tools that could lead to scalable, practical ‘ELISA-like’ assays to screen blood, CSF and other biological 
samples, with important implications for public health, diagnosis and therapeutic development. As 
aggregation is a sequence-specific process nucleated by specific short aggregation-prone sequences, such 
interactions could be exploited instead of, or in addition to classic antibody-based assays to detect and 
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potentially prevent amyloid formation39. Other potentially useful approaches include Protein Misfolded 
Cyclic Amplification (PMCA), a labour-intensive process which is however 100% sensitive and 99% 
analytically specific for detection of prions in the plasma of individuals with (pre)symptomatic variant 
CJD40,41. PCMA can also be used to distinguish between different  α-synuclein strains42, and reproduce 
some aspects of α-synuclein aggregation and seeded propagation43. Recently, the use of Real-Time 
Quaking Induced Conversion (RT-QuIC), which has significantly improved the diagnosis of sporadic CJD in 
CSF, olfactory-mucosa and skin, showed promise in detecting the seeding activity associated with 
synucleinopathies and tauopathies44–48. The development of low-cost, high-throughput, sensitive assays 
for proteopathic seeds would eventually enable direct testing for the presence of proteopathic seeds on 
neurosurgical instruments49. 
In parallel, larger epidemiological studies are needed to ascertain the prevalence of CAA pathology in 
patients with a medical history of neurosurgery in early life. Such investigations must take into account 
that it may take at least two decades to develop pathologically detectable Aβ deposits and even longer to 
manifest clinically as CAA. These studies could employ Magnetic Resonance Imaging (MRI) and amyloid 
PET imaging to define the prevalence of CAA in younger adults (<50 years) following neurosurgical 
procedures in childhood. At the same time, retrospective studies mining healthcare record systems to 
check prior history of neurosurgical intervention in all patients presenting with early onset CAA could help 
to ascertain the cause and extent of iatrogenic CAA. Testing and evaluating surgical tool decontamination 
procedures with affordable enzyme-based detergents similar to those previously developed for prion 
decontamination50 may also help to limit the potential risk of surgical instrument-based transmission of 
proteopathic seeds that are known to resist conventional sterilization procedures.  
Regarding the potential risk of blood-based amyloid transmissibility, building longitudinal cohorts of 
individuals at potential risk (e.g. haemophiliacs who may repeatedly receive large amount of plasma-
derived medicinal products) with periodic follow-ups including MRI and/or amyloid PET imaging and 
extending long-term vigilance studies based on the SCANDAT model30 could help provide definitive 
evidence. Rigorous health record systems enable tracking of donor/recipients for other therapies that 
might carry a risk of proteopathic seed transmission, such as future neural stem cell transplantation. 
Moreover, biobanks of both blood donors and recipients could be tested using the rapidly improving blood 
tests for neurodegenerative pathologies40, including neurofilament light chain (general 
neurodegeneration), phosphorylated tau (Aβ and tau pathology), Aβ42/Aβ40 ratio (amyloid pathology)51,52 
and phosphorylated Ser129 or C-terminally truncated α-synuclein53. Further studies on animal models, 
such as blood transfer from aged mice with brain amyloid pathology to wild-type recipient animals and 
parabiosis paradigms11, could also help investigate potential transmissibility mechanisms in more detail.  
Finally, transparent communication on the nature of the potential risk based on the available scientific 
evidence and on the areas of remaining uncertainty, together with clear statements on which 
measures/research are undertaken, are crucial. Governments and health agencies also need to relay 
scientific information to the general public, health workers and patients, perform scientifically founded 
risk assessment, and regularly re-evaluate policies in the light of epidemiological information 
accumulating over time and the emergence of key novel evidence. At this moment there is no scientific 
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evidence that supports more drastic measures than the ones we summarize in the Supplementary 
material (appendix, p1-p4). 
  
Conclusions 
There is currently no evidence to suggest that AD or other human neurodegenerative diseases (except 
CJD) are transmissible via iatrogenic ways. However, the potential iatrogenic transmission of Aβ pathology 
(CAA) calls for more systematic monitoring of individuals subject to early life neurosurgical procedures 
and for longer-term vigilance studies on blood transfusion. In addition, understanding the molecular 
nature of the proteopathic seeds and the development of scalable assays for seed detection will be crucial 
to provide definitive evidence on the risk of amyloid transmissibility. Further work is also needed to 
carefully monitor the possible spreading of other proteopathic seeds like alpha-synuclein and Tau from 
patient to patient, although currently no evidence apart from animal experimentation is available.  
 
Box 1. Terminology 
There is currently no generally accepted, standard terminology for protein aggregates 
characteristic of proteinopathies. Two diverging trends exist in the field54, with a focus either on 
the similarities - in terms of protein structure and ability to template their own polymerization - or 
differences - in terms of infectivity - between the original “prions” and other misfolded proteins 
associated with neurodegenerative diseases. 
●     Prions were defined as proteinaceous infectious particles in 198255, originally to designate 
the agents causing transmissible spongiform encephalopathies (TSEs). Over the years, the 
term has been semantically broadened and is now sometimes used irrespective of their 
infectivity56. 
● Prion-like57, prionoid58 and quasi-prion59 are the most frequent alternative names for 
proteins that have properties reminiscent of prions, in particular regarding their ability to 
seed proteins of the same kind and transmit between cells. We do not use them here as 
they are stressing the similarities between amyloids and prions, which might create 
confusion in the public. For instance while the prion disease Bovine spongiform 
encephaloptahy can be transmitted orally by eating contaminated meat, this is not yet 
observed with any of the proteins that are causing neurodegenerative disorders like AD or 
PD.  
● Propagons60 was proposed by the yeast research community instead of the term “yeast 
prions” for the non-pathogenic, transmissible amyloids that mediate protein-based 
epigenetic inheritance. 
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● Proteopathic seeds5 is used here in this Personal View. It is a more neutral term indicating 
the abnormally folded proteins that cause neurodegenerative disorders.    
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Search strategy and selection criteria 
References for this Personal View were identified by searching PubMed (6, 3, 2019 - 18, 5, 2020) for 
articles, case reports and clinical studies. The search terms used were “Abeta” or “amyloid” in 
combination with the terms “iatrogenic” and “dura mater” or “growth hormone”. There were no language 
restrictions. Further publications were identified by searching the list of references cited in the articles 
that were reviewed. The final reference list, including all search results reporting histopathological 
analysis of human biomaterial for the presence of amyloids, was generated on the basis of relevance to 
the topic of this Personal View by the participants to the Amyloid Transmissibility Workshop held in 
London on October 7-8, 2019. 
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